Actively Recruiting
The Effects on Auditory Function of RADiotherapy and Chemotherapy Treatments for Head and Neck Tumours (EARAD)
Led by University of Manchester · Updated on 2024-05-08
100
Participants Needed
1
Research Sites
395 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Radiotherapy and combined radiotherapy and chemotherapy are used to treat most tumours in the head and neck region. Unfortunately, these treatments often result in hearing loss and tinnitus that has a negative impact on quality of life. This study will use a battery of sensitive tests, including measures of hair cell and neural function, before and after treatment, to measure the effects of these treatments on auditory function. The results will be compared with the individual radiotherapy dose characteristics, using state-of-the-art data mining technology, to identify the auditory substructures that are most sensitive to radiation with respect to the effects on auditory function. The data will provide the basis for new dose constraints to limit radiation doses to any identified substructures and to minimise loss in hearing ability for patients undergoing treatment for head and neck cancer.
CONDITIONS
Official Title
The Effects on Auditory Function of RADiotherapy and Chemotherapy Treatments for Head and Neck Tumours (EARAD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with head and neck cancer
- An MDT treatment decision of radiotherapy with or without cisplatin based chemotherapy
- Previously diagnosed and treated for head and neck cancer (retrospective cohort)
- Radiotherapy treatment to one side of the head (retrospective cohort)
- Within 5 years post-treatment (retrospective cohort)
- Hearing loss greater than 20 dB HL (average from 0.25 to 4 kHz) for hearing-impaired controls
You will not qualify if you...
- Hearing loss greater than 25 dB HL (average from 0.25 to 4 kHz) prior to the study
- Existing hearing loss requiring hearing aid
- An MDT treatment decision of carboplatin based chemotherapy
- Involved in another research project with known ototoxic treatment
- Unable to give informed consent
- Hearing loss greater than 20 dB HL at any octave frequency from 0.25 to 4 kHz for normal-hearing controls
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Christie NHS Foundation Trust
Manchester, United Kingdom, M20 4BX
Actively Recruiting
Research Team
C
Chris Plack, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here